{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:09:59Z","timestamp":1793138999373,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.conctc.2020.100537","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T16:40:29Z","timestamp":1580229629000},"page":"100537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial"],"prefix":"10.1016","volume":"17","author":[{"given":"Alkomiet","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Roeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hansbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Oviedo-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie K.","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-788X","authenticated-orcid":false,"given":"Irina","family":"Papazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"L\u00f6hrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-6167","authenticated-orcid":false,"given":"Elias","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Maurus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Strube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-3420","authenticated-orcid":false,"given":"Moritz J.","family":"Rossner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schneider-Axmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"G\u00f6rlitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Karch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Egert-Schwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Schossow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Falkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2020.100537_bib1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15252\/emmm.201606650","article-title":"From neuroleptics to neuroscience and from Pavlov to psychotherapy: more than just the \"emperor's new treatments\" for mental illnesses?","volume":"8","author":"Margraf","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.conctc.2020.100537_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World federation of societies of biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J. Biol. Psychiatr."},{"issue":"Suppl 1","key":"10.1016\/j.conctc.2020.100537_bib3","first-page":"38","article-title":"Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia","volume":"19","author":"Carbon","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.conctc.2020.100537_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","article-title":"Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis","volume":"70","author":"Desamericq","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.conctc.2020.100537_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.conctc.2020.100537_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","article-title":"A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects","volume":"89","author":"Woodward","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.conctc.2020.100537_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.conctc.2020.100537_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.conctc.2020.100537_bib11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib12","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/s41386-018-0169-7","article-title":"Altered ErbB4 splicing and cortical parvalbumin interneuron dysfunction in schizophrenia and mood disorders","volume":"43","author":"Chung","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conctc.2020.100537_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005920","article-title":"Association between ErbB4 single nucleotide polymorphisms and susceptibility to schizophrenia: a meta-analysis of case-control studies","volume":"96","author":"Feng","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.conctc.2020.100537_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn2392","article-title":"Neuregulin 1 in neural development, synaptic plasticity and schizophrenia","volume":"9","author":"Mei","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.conctc.2020.100537_bib15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/cercor\/bhr223","article-title":"Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation","volume":"22","author":"Deakin","year":"2012","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.conctc.2020.100537_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biopsych.2005.11.002","article-title":"Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology","volume":"60","author":"Harrison","year":"2006","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.25","article-title":"Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity","volume":"2","author":"Weickert","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.conctc.2020.100537_bib18","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1073\/pnas.0602002103","article-title":"Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease","volume":"103","author":"Law","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.conctc.2020.100537_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm1418","article-title":"Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia","volume":"12","author":"Hahn","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.conctc.2020.100537_bib20","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/WNR.0b013e328330f6e7","article-title":"Behavioural characterization of neuregulin 1 type I overexpressing transgenic mice","volume":"20","author":"Deakin","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.conctc.2020.100537_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014185","article-title":"Phenotypic characterization of transgenic mice overexpressing neuregulin-1","volume":"5","author":"Kato","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.conctc.2020.100537_bib22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.celrep.2014.07.026","article-title":"Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic plasticity","volume":"8","author":"Agarwal","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.conctc.2020.100537_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.neuron.2013.03.028","article-title":"Reversal of behavioral deficits and synaptic dysfunction in mice overexpressing neuregulin 1","volume":"78","author":"Yin","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.conctc.2020.100537_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.neuron.2013.05.004","article-title":"A new beginning for a broken mind: balancing neuregulin 1 reverses synaptic dysfunction","volume":"78","author":"Marin","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.conctc.2020.100537_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.biopsych.2013.09.026","article-title":"Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice","volume":"76","author":"Luo","year":"2014","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib26","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.15252\/emmm.201707691","article-title":"Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice","volume":"9","author":"Wehr","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"Suppl 20","key":"10.1016\/j.conctc.2020.100537_bib27","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hbm.20131","article-title":"N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies","volume":"25","author":"Owen","year":"2005","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.conctc.2020.100537_bib29","series-title":"Annual Review of Clinical Psychology","first-page":"321","article-title":"The cognitive neuroscience of schizophrenia","author":"Barch","year":"2005"},{"key":"10.1016\/j.conctc.2020.100537_bib30","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jpsychires.2009.04.004","article-title":"Inefficient neural activity in patients with schizophrenia and nonpsychotic relatives of schizophrenic patients: evidence from a working memory task","volume":"43","author":"Karch","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.conctc.2020.100537_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.eplepsyres.2009.09.002","article-title":"Unique and shared validity of the \"Wechsler logical memory test\", the \"California verbal learning test\", and the \"verbal learning and memory test\" in patients with epilepsy","volume":"87","author":"Helmstaedter","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.conctc.2020.100537_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","article-title":"Trail Making Test A and B: normative data stratified by age and education","volume":"19","author":"Tombaugh","year":"2004","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.conctc.2020.100537_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1017\/S135561770410307X","article-title":"The d2 Test of attention: construct validity and extensions in scoring techniques","volume":"10","author":"Bates","year":"2004","journal-title":"J. Int. Neuropsychol. Soc. : JINS"},{"key":"10.1016\/j.conctc.2020.100537_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.conctc.2020.100537_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the calgary depression scale","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatr. Suppl."},{"key":"10.1016\/j.conctc.2020.100537_bib37","series-title":"CGI: Clinical Global Impressions","author":"Guy","year":"1976"},{"key":"10.1016\/j.conctc.2020.100537_bib38","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.conctc.2020.100537_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand. Suppl."},{"key":"10.1016\/j.conctc.2020.100537_bib40","first-page":"405","article-title":"Transcranial brain stimulation in schizophrenia: targeting cortical excitability, connectivity and plasticity","volume":"20","author":"Hasan","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.conctc.2020.100537_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"10.1016\/j.conctc.2020.100537_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/npp.2011.106","article-title":"Translating discoveries into medicine: psychiatric drug development in 2011","volume":"37","author":"Brady","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conctc.2020.100537_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004873","article-title":"Next-generation treatments for mental disorders","volume":"4","author":"Insel","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.conctc.2020.100537_bib44","series-title":"Stops Phase III Development of Pomaglumetad Methionil for the Treatment of Schizophrenia Based on Efficacy Results","author":"Lilly","year":"2012"},{"key":"10.1016\/j.conctc.2020.100537_bib45","series-title":"Roche Provides Update on the First Two of Six Phase III Studies of Bitopertin in Schizophrenia","author":"Roche","year":"2013"},{"key":"10.1016\/j.conctc.2020.100537_bib46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nmeth967","article-title":"Monitoring regulated protein-protein interactions using split TEV","volume":"3","author":"Wehr","year":"2006","journal-title":"Nat. Methods"},{"key":"10.1016\/j.conctc.2020.100537_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1472-6750-8-55","article-title":"Analysis of transient phosphorylation-dependent protein-protein interactions in living mammalian cells using split-TEV","volume":"8","author":"Wehr","year":"2008","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.conctc.2020.100537_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/483269a","article-title":"Drug research: a plan for mental illness","volume":"483","author":"Insel","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.conctc.2020.100537_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tics.2011.11.015","article-title":"Cognition in schizophrenia: core psychological and neural mechanisms","volume":"16","author":"Barch","year":"2012","journal-title":"Trends Cognit. Sci."},{"key":"10.1016\/j.conctc.2020.100537_bib50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/nedt.2006.2.4.531","article-title":"Cognitive deficits and functional outcome in schizophrenia","volume":"2","author":"Bowie","year":"2006","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.conctc.2020.100537_bib51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420300211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420300211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:01:40Z","timestamp":1762520500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865420300211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":51,"alternative-id":["S2451865420300211"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100537","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100537"}}